240 related articles for article (PubMed ID: 33926362)
1. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.
Al-Samkari H; Soff GA
Expert Rev Hematol; 2021 May; 14(5):437-448. PubMed ID: 33926362
[No Abstract] [Full Text] [Related]
2. Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Hematol; 2023 May; 16(5):365-375. PubMed ID: 37039010
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Al-Samkari H
Blood Rev; 2024 Jan; 63():101139. PubMed ID: 37914568
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.
Al-Samkari H
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):286-295. PubMed ID: 36485134
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.
Chen W; Liu Y; Li L; Zeng X
BMC Pharmacol Toxicol; 2023 Dec; 24(1):71. PubMed ID: 38041150
[TBL] [Abstract][Full Text] [Related]
8. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Song AB; Goodarzi K; Karp Leaf R; Kuter DJ; Al-Samkari H
Am J Hematol; 2021 Dec; 96(12):1563-1568. PubMed ID: 34453757
[TBL] [Abstract][Full Text] [Related]
11. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Soff GA; Ray-Coquard I; Rivera LJM; Fryzek J; Mullins M; Bylsma LC; Park JK
PLoS One; 2022; 17(6):e0257673. PubMed ID: 35679540
[TBL] [Abstract][Full Text] [Related]
12. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
14. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
16. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
Al-Samkari H; Parnes AD; Goodarzi K; Weitzman JI; Connors JM; Kuter DJ
Haematologica; 2021 Apr; 106(4):1148-1157. PubMed ID: 32499239
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
18. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
20. What is the role of novel thrombopoietic agents in the management of acute leukemia?
Kuter DJ
Best Pract Res Clin Haematol; 2016 Dec; 29(4):372-378. PubMed ID: 27890262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]